"Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
    
			
			
				
				
					
						| Descriptor ID | D016044 | 
					
						| MeSH Number(s) | D08.811.913.696.620.682.725.500.500 D12.776.602.500.500.100 D12.776.624.664.500.100 D12.776.624.664.700.171.500 | 
					
						| Concept/Terms | Fusion Proteins, bcr-ablFusion Proteins, bcr-ablFusion Proteins, bcr ablbcr-abl Fusion Proteinsbcr abl Fusion ProteinsBcr-Abl Tyrosine KinaseBcr Abl Tyrosine KinaseKinase, Bcr-Abl TyrosineTyrosine Kinase, Bcr-Abl
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Fusion Proteins, bcr-abl".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Fusion Proteins, bcr-abl".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Fusion Proteins, bcr-abl" by people in this website by year, and whether "Fusion Proteins, bcr-abl" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2015 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.
						
					
								- 
								Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia. 2015 Jul; 29(7):1514-23.